Considering AD, the diagnostic process is conclusive for AD cause when CSF biomarkers indicate brain amyloidosis and tau pathology (based on reduced CSF Aβ42 or Aβ42/Aβ40 ratio and elevated p-tau protein) (18). The gene discussed is MAPT; the disease is Alzheimer disease.